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Abstract 
 
Background- Coronary artery spasm plays an important role in the pathogenesis of ischemic 
heart disease; however, its role in sudden cardiac death remains to be fully elucidated.  The 
clinical characteristics and outcomes of patients with vasospastic angina (VSA) were 
examined in our nationwide multicenter registry by the Japanese Coronary Spasm 
Association. 
Methods and Results- Between September 2007 and December 2008, 1,429 patients with 
VSA (M/F, 1,090/339: median 66 years) were identified.  They were characterized by a high 
prevalence of smoking and included 35 patients who survived out-of-hospital cardiac arrest 
(OHCA).  The OHCA survivors, as compared with the remaining 1,394 non-OHCA patients, 
were characterized by younger age (median 58 vs. 66 years, P<0.001) and higher incidence of 
left anterior descending coronary artery spasm (72 vs. 53%, P<0.05).  In the OHCA 
survivors, 14 patients underwent implantable cardioverter defibrillator (ICD) implantation 
while intensively treated with calcium channel blockers.  The survival rate free from major 
adverse cardiac events (MACE) was significantly lower in the OHCA survivors compared 
with the non-OHCA patients (72 vs. 92% at 5 years, P<0.001), including appropriate ICD 
shocks for ventricular fibrillation in 2 patients.  Multivariable analysis revealed that OHCA 
event was significantly correlated with MACE (hazard ratio, 3.25; 95% confidence interval, 
1.39 to 7.61; P<0.01). 
Conclusions- These results from the largest observational study of VSA indicate that 
vasospasm patients who survived OHCA are high risk population.  Further studies are 
needed to determine whether ICD therapy improves the patients’ prognosis. 
 
Key words; acetylcholine; angina; arrhythmia; prognosis; vasospasm 
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Introduction 
 
Out-of-hospital cardiac arrest (OHCA) is a major public health problem.  Its estimated 
number is 300,000 to 400,000 per year in the United States.1)  A prospective study showed 
an incidence of 53/100,000 per year, with 25% of victims being younger than 65 years.2)  
Causes of OHCA are strongly associated with coronary artery disease as evidenced at autopsy 
and the survival rate from OHCA still remains to be substantially improved.1)  Importantly, a 
significant number of OHCA cases remained unexplained if victims have no structural 
abnormalities (e.g. organic coronary stenosis) in the post-mortem analysis.3)  This finding 
strongly suggests that functional abnormalities of the coronary artery are also involved in the 
pathogenesis of OHCA.4) 
Recently, the prevalence of early access to emergency medical service, early bystander 
cardiopulmonary resuscitation and early defibrillation has been increasing with a resultant 
improvement of the survival rate from OHCA.5)-7)  The progress of the chain of survival now 
opens the window to elucidate the underlying mechanisms of patients who survived OHCA.  
Coronary artery spasm plays an important role in the pathogenesis of a wide variety of 
ischemic heart disease, including sudden cardiac death, and thus could be one of the most 
important functional abnormalities of the coronary artery.8)-10)  Since Prinzmetal et al. firstly 
described vasospastic angina (VSA) as a “variant angina” in 1959,11) the prognostic studies of 
VSA patients were performed in Western countries and Japan.12)-19)  These studies of a few 
hundred of patients demonstrated that the presence of organic coronary stenosis, multivessel 
spasm and smoking were among one of the most important predictors of clinical events,13)-16), 
18)-20)
 and that calcium channel blockers (CCBs) were effective in reduction of the risk of 
cardiac events in VSA patients.13), 15), 16), 19)  However, little is known about the clinical 
characteristics and long-term prognosis of VSA patients who survived OHCA, except for the 
previous single center studies with a small number of patients.21), 22) 
In the present study, the nationwide multicenter registry study with the large patient 
number was conducted by the Japanese Coronary Spasm Association to elucidate the clinical 
characteristics and long-term prognosis of VSA patients, especially those who survived 
OHCA. 
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Methods 
 
The Japanese Coronary Spasm Association was founded in 2006 and currently 68 institutes 
participate.  The present study was approved by the institutional review boards or ethics 
committees of all participating institutions. 
 
Study Patients 
All VSA patients were referred or admitted to the participating institutes and were originally 
diagnosed between April 1, 2003 and December 31, 2008.  The registration was made 
between September 1, 2007 and December 31, 2008.  In the present study, data collection 
was conducted in a retrospective fashion for patients seen before September 2007 and in a 
prospective manner for those seen after that date.  The diagnosis of VSA was made based on 
the Guidelines for Diagnosis and Treatment of Patients with Vasospastic Angina of the 
Japanese Circulation Society.23)  The definition of VSA included an angina attack at rest 
and/or on effort, accompanied by a transient ECG ST-segment elevation or depression of 
more than 0.1 mV or a newly appearance of negative U wave in at least 2 related leads, and/or 
a total or subtotal coronary artery narrowing during the provocation test of coronary spasm, 
accompanied by chest pain and/or ischemic ECG changes mentioned above. 
 
Data Collection 
The demographic and clinical data were submitted to a central database, including age, gender, 
coronary risk factors, family history, type of angina episodes, circadian distribution of angina 
attacks, leads of ST-segment elevation or depression and arrhythmias during spontaneous or 
provoked angina attack, location of coronary spasm, device therapy such as implantable 
cardioverter defibrillator (ICD), medical therapy and its adherence.  The reduction and 
discontinuation of medication was defined as having a gap in use of any medication and no 
use of medication, respectively.  Hypertension, dyslipidemia and diabetes mellitus were 
diagnosed based on the guidelines of the Japanese Society of Hypertension, Japan 
Atherosclerosis Society, and Japan Diabetes Society, respectively.24)-26)  Significant coronary 
stenosis was defined as more than 50% of luminal narrowing of major coronary arteries 
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evaluated by coronary angiography.  OHCA was defined as the cessation of cardiac 
mechanical activity as confirmed by the absence of signs of circulation.27) 
 
Endpoints 
The primary endpoint was major adverse cardiac events (MACE), including cardiac death, 
non-fatal myocardial infarction, hospitalization due to unstable angina pectoris and heart 
failure and appropriate ICD shocks during the follow-up period which began at the date of 
original VSA diagnosis.  The secondary endpoint was all cause mortality.  Cardiac death 
was defined as sudden death (i.e. death occurring unexpectedly without any apparent 
symptoms or within 1 hour of symptom onset, or non-witnessed death in the absence of any 
other possible cause) or death associated with acute myocardial infarction.  Acute 
myocardial infarction was defined in patients with prolonged (>30 min) chest pain, associated 
with ST-segment changes and elevated levels of cardiac enzymes.  Unstable angina pectoris 
was diagnosed if chest discomfort or pain became recurrent or worsening along with ischemic 
ECG changes.  Heart failure was diagnosed if a patient showed signs of exertional dyspnea, 
orthopnea, rales in more than one-third of the lung fields, elevated jugular venous pressure or 
pulmonary congestion on chest X-ray related to cardiac dysfunction. 
 
Statistics 
Continuous variables are presented as medians and interquartile ranges and categorical 
variables as percentages.  Group comparisons were performed with Mann-Whitney test for 
continuous variables, Fisher’s exact test for categorical variables and log-rank test for survival 
curves.  Survival free from death and MACE were analyzed by the Kaplan-Meier method.  
Multivariable analysis of correlated factors of MACE was performed with a Cox proportional 
hazard model.  Variables depicted by univariable analysis to be correlated with MACE and 
well-known predictive variables were subjected to the forced entry method.  The 
proportional hazards assumption was examined with the log minus log plot.  Hazard ratio 
(HR) and 95% confidence interval (CI) were also calculated.  A value of P<0.05 was 
considered to be statistically significant. 
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Results 
 
Clinical Characteristics of Patients with VSA 
Among a total of 1,528 VSA patients registered from 47 institutes, 99 patients were excluded 
because they did not meet the diagnostic criteria (n=7) or the inclusion criteria (n=92).  
Finally, 1,429 patients were studied (Figure 1).  The diagnosis of VSA was made between 
April 2003 and September 2007 in 1,276 patients (89%), and between September 2007 and 
December 2008 in the remaining 153 patients.  The clinical characteristics of those patients 
are summarized in Table 1.  Among the coronary risk factors, smoking was observed most 
frequently (~60%), especially in male patients.  The prevalence of family history of ischemic 
heart diseases, previous myocardial infarction and the existence of organic coronary stenosis 
was relatively low (~10%).  When compared with the female patients, the male patients were 
characterized by younger age, higher incidences of previous myocardial infarction, organic 
coronary stenosis, angina attack with ST-segment elevation and lower incidence of family 
history of ischemic heart diseases.  In contrast, no sex difference was noted in the prevalence 
of arrhythmia during spontaneous attacks, including OHCA (Table 1).  Among the 1,317 
patients in whom ECG was recorded during spontaneous attack, significant ST-segment 
elevation and depression was documented in 272 and 121 patients, respectively. 
Among the registered patients except 169 patients (12%, not recorded), angina attacks 
occurred exclusively at rest in 634 patients (44%), whereas it occurred predominantly at rest 
but was also induced by effort in 513 patients (36%).  In 113 patients (8%), angina attacks 
were induced only by effort.  In 658 patients, typical circadian pattern was identified mostly 
from midnight to early morning as follows; from 0 am to 4 am (n=160), 4 am to 8 am (n=377), 
8 am to noon (n=122), noon to 4 pm (n=36), 4 pm to 8 pm (n=40) and 8 pm to 12 pm (n=66). 
Provocation test was performed during coronary angiography in 1,244 patients with 
either acetylcholine (n=713, 57.3%), ergonovine (n=497, 40.0%), both of them (n=23, 1.8%) 
or others (e.g., hyperventilation) (n=11, 0.9%).  The prevalence of arrhythmic events during 
provocation test (n=85, 6.8%) was similar with that during spontaneous attack (n=107, 7.5%) 
(Table 2). 
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Medical Treatments 
In the present study, 1,331 patients (93%) were treated with CCBs, either CCBs alone (48%) 
or combination of CCBs, and long-acting nitrates including nicorandil (45%).  Most of the 
patients (n=1162, 81%) were treated with one type of CCB; delayed- or modified-release 
formulations of first generation of CCBs in 814 and the second and third generation of CCBs 
with longer plasma half-lives in 348.28)  Anti-platelet agents were used in 669 patients (47%).  
However, the use of β-blockers was limited to 61 patients (4%) in the present study. 
 
Prognostic Factors of MACE by Multivariate Analysis 
During the median follow-up period of 32 months (interquartile range, 17 to 46 months; 
standard error, 13.6), 19 patients (1.3%) died, where 6 patients had cardiac death.  MACE 
occurred in 85 patients (5.9%), including myocardial infarction (n=9), hospitalization due to 
unstable angina (n=68) and heart failure (n=4) and appropriate ICD shocks (n=2).  Overall 
5-year survival rate free from all cause death or MACE was 98% and 91%, respectively 
(Figure 2).  Especially, 5-year survival rate free from non-fatal myocardial infarction was 
high (99%). 
    Multivariable analysis demonstrated that in addition to the established prognostic factors 
(smoking, spontaneous attack with ST-segment elevation, multivessel spasm and significant 
organic stenosis in major coronary arteries), history of OHCA was significantly correlated 
with MACE (Table 3). 
Among the study patients, reduction or discontinuation of medication was observed in 25 
patients (1.7%) including 1 OHCA survivor.  Although the clinical characteristics of patients 
with and those without reduction or discontinuation of medication were comparable (Table 4), 
the rate of cardiac death and non-fatal myocardial infarction in patients in whom medications 
were reduced or discontinued (8%, 2 out of 25 patients) was 10-fold higher than that in the 
patients with continued medications (0.7%, 10 out of 1,404 patients, P=0.017) (Figure 4). 
 
VSA Patients Who Survived Out-of-Hospital Cardiac Arrest due to Coronary Artery 
Spasm 
The present study included 35 VSA patients who survived OHCA as their first manifestation 
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of clinical events in 14 institutes, 7 of which had the emergency care department.  In these 7 
hospitals, coronary artery spasm was documented in 22 patients (6.0%) out of 365 patients 
resuscitated from OHCA of cardiac origin between April 1, 2003, and December 31, 2008.  
The OHCA survivors with VSA were characterized by younger age and higher incidence of 
coronary spasm in the left anterior descending coronary artery as compared with the 
remaining non-OHCA patients (Table 5).  However, the prevalence of significant coronary 
stenosis was comparable between the 2 groups.  Medical treatments for patients with and 
those without OHCA are summarized in Table 6.  There was no difference between 2 groups 
except for β-blockers.  In 35 OHCA survivors, 14 patients (40%) underwent ICD 
implantation for the secondary prevention of sudden cardiac death.  MACE occurred in 6 out 
of 36 OHCA survivors (17%) during follow-up period; cardiac death in 1, non-fatal 
myocardial infarction in 1, hospitalization due to unstable angina in 3.  In addition, 
appropriate ICD shocks for VF were documented in 2 out of the 14 OHCA survivors with 
ICD implantation during intensive medical treatment (Table 7).  These 2 patients had a 
Brugada-type ECG pattern and had VF induced by electrophysiological study.  The clinical 
characteristics and medical treatments of patients with and those without ICD implantation 
are shown in Table 8.  Sudden cardiac death occurred in one patient without ICD who 
terminated medication himself before the fatal event.  Despite the comparable incidence of 
all cause mortality (Figure 3A), the event-free survival rate was significantly lower in the 
OHCA survivors as compared with the non-OHCA patients (72 vs. 92% at 5 years, P<0.001) 
(Figure 3B).  In subgroup analysis between OHCA survivors who did (n=5) and did not 
(n=30) have later adverse events, left ventricular ejection fraction and the prevalence of 
significant coronary stenosis was comparable (Table 9).  
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Discussion 
 
The present multicenter study with 1,429 patients is the largest observational study of VSA, 
where the patients were registered based on the standardized criteria by the Japanese 
Circulation Society.23)  The present study also is characterized by the fact that ~400 VSA 
cases with documented spontaneous attacks were included, which enhances the scientific 
level of the study.  In the present study, it is demonstrated that VSA patients who survived 
OHCA are particularly high-risk population even in the current era with long-acting CCBs. 
 
VSA Patients Who Survived OHCA as a High-Risk Population 
In 2000’s, early initiation of cardiopulmonary resuscitation and the widespread use of 
defibrillation programs have saved many patients with OHCA, making subsequent care of 
these patients more important than ever.29)  Accumulating evidence indicates that cardiac 
arrest in the absence of organic heart disease is more common than previously expected.30)  
In the autopsy studies in patients with sudden cardiac death, the prevalence of no significant 
coronary stenosis was higher in Japanese (26%) than in European populations (4%),31), 32) 
indicating the potential importance of functional coronary abnormalities in the pathogenesis 
of sudden cardiac death in Japanese.  In the present study, coronary spasm was documented 
in 6% of the patients resuscitated from OHCA of cardiac origin.  The prevalence of 
vasospasm in OHCA patients appeared to be doubled in comparison with that (3%) reported 
in the previous study participating 4 French emergency units.30) Because the racial 
differences may affect the diagnostic and therapeutic strategies (e.g. use of the provocation 
test), the study with Japanese patients should provide important information for better 
understanding of the pathogenesis of VSA. 
In the present study, the incidence of OHCA in VSA patients was 2.4%, which is 50-fold 
higher than that (0.05%) in the general Japanese population,33) indicating that VSA patients, 
especially those who survived OHCA, are high-risk population.  Despite comparable 
medical treatments, the event-free survival rate in the OHCA survivors was much lower than 
in the non-OHCA patients (Figure 3).  The event of OHCA and worse clinical outcome may 
not be coincidental but could be explained in part by severe myocardial ischemia due to left 
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anterior descending artery spasm (Table 4).34)  The multivariable analysis also 
demonstrated that prior history of OHCA events was a novel and significant correlated factor 
of MACE in VSA patients (Table 3).  While life-threatening arrhythmias may be related to 
increased disease activity of coronary spasm,13), 16) a potential involvement of an arrhythmic 
substrate in association with ventricular repolarization abnormalities has been suggested in 
the previous study.35), 36)  In patients with variant angina complicated by cardiac arrest, the 
prevalence of QT dispersion was significantly higher compared with uncomplicated 
patients.35)  We also have recently reported that OHCA survivors with coronary spasm 
demonstrated concomitant idiopathic VF, indicating heterogeneity of the underlying 
mechanisms.36) 
The association of potentially lethal ischemia-induced ventricular arrhythmias may 
justify the use of an ICD.37)  Meisel et al. reported both the efficacy and limitation of ICD 
therapy in patients with refractory variant angina.22)  In their 7 patients with variant angina 
complicated by VF, appropriate ICD shocks were documented in 4 patients, but one patient 
died of electromechanical dissociation even under intensive medical treatment with CCBs.  
However, in the previous studies with a small number of patients (n=6~7), the prognosis was 
favorable in survivors of cardiac arrest due to coronary spasm who did not receive ICD.10), 21)  
To determine the indication of ICD therapy for OHCA survivors with VSA, the risk 
stratification for recurrence of cardiac arrest is required.  We previously reported that the 
dual induction tests for coronary spasm and VF potentially provide useful information of 
individualized treatment.36)   It remains to be examined in a future multicenter study 
whether ICD therapy can improve the prognosis of OHCA survivors with coronary spasm. 
 
Importance of Continued Medical Treatment for VSA 
Following withdrawal of CCB, silent myocardial ischemia with fatal arrhythmias38) and a 
rebound phenomenon of the spasm39), 40) could occur.  In the present study, Fisher’s exact test 
also demonstrated that the incidence of cardiac death and non-fatal myocardial infarction was 
significantly increased in patients in whom medications were reduced or discontinued.  
These findings indicate that medications should not be withdrawn carelessly even if 
symptomatic attacks seem to be controlled.  Although CCBs remain the main stay of the 
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current clinical practice, it has been reported that 6-month CCBs therapy did not completely 
normalize coronary vasoconstricting responses to acetylcholine despite the absence of 
symptomatic angina.41)  Even after 1-year CCB therapy, myocardial fatty acid metabolic 
images assessed using 123I-15-(p-iodophenyl) -3-R,S-methyl pentadecanoic acid have been 
reported to appear abnormal in VSA patients.42)  These findings suggest that there are also 
limitations of these classes of drug.  Recently, the accumulating evidence demonstrated that 
small GTPase RhoA and its downstream effector Rho-kinase play a central role by increased 
Ca2+ sensitivity of vascular smooth muscle cells in the molecular mechanism of coronary 
vasospasm in animal models and VSA patients.43)  The inhibition of Rho-kinase with fasudil 
has been reported to result in the disappearance of coronary vasospastic activity44) and is a 
novel therapeutic option that could target specific abnormalities with a resultant remission of 
VSA. 
 
Changing Characteristics of VSA Patients 
In association with the epidemics of obesity and metabolic syndrome, the general population 
has been rapidly growing older and the westernization of lifestyle has been progressing, 
especially in Japan.45)  Thus, the present nationwide multicenter registry study also focuses 
on the clinical characteristics and outcomes of VSA patients in the current era of 2000’s. 
Coronary spasm was most frequently noted in middle-aged male, who otherwise did not 
exhibit coronary risk factors except for higher prevalence of smoking.  In male VSA patients 
(Table 1), the prevalence of smoking still remains high (~70%), although a survey on the 
smoking rates of Japanese general population conducted by Japan Tobacco Inc. revealed that 
40% of Japanese males and 13% of females smoked in 2008, which was rapidly decreasing in 
recent years.46)  Because smoking is a crucial prognostic factor of VSA patients,20) the 
importance of quitting smoking should be emphasized.  The lower incidence of previous 
myocardial infarction and of organic coronary disease were comparable with the previous 
report on the clinical characteristics of Japanese patients as compared with Caucasian 
patients.18) 
    Several prognostic studies with a few hundreds of patients were performed in 1980’s.  
Yasue et al. reported that 5-year survival rate free from death or myocardial infarction was 
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97% and 83% in 245 patients.19)  In general, as reported in the previous comparative study,18) 
the prognosis was much worse in Western population than in Japanese population.14), 16)  In 
the current era, the clinical outcome of VSA patients appears to be further improved in 2000’s 
as compared with 1980’.14), 16), 18), 19) 
 
Limitations of the Study 
Several limitations should be mentioned for the present study.  First, the present study is a 
retrospective observational study and thus the association found in the present study is not 
necessarily causal.  In order to address this important issue, the prospective studies have 
been started by our Japanese Coronary Spasm Association.  Second, the follow-up period 
was variable and it is highly possible that many arrhythmic events were missed during the 
periods of time that the patients were not being monitored.  In addition, there is no 
information available about patients who did not survive the pre-hospital OHCA.  Third, 
complex composite primary endpoint, including ICD shocks, was used in the present study.  
Appropriate ICD shocks are not certainly a surrogate for sudden cardiac death.  Fourth, 
management decisions were left to the discretion of each attending physician.  Fifth, there is 
no sufficient information available about the date of reduction or discontinuation of 
medications and thus this variable was not included in the present Cox proportional hazard 
model.  Sixth, further studies are needed to ascertain the present finding of the relatively 
lower prevalence of dyslipidemia in the OHCA survivors.  However, despite these 
limitations, the present findings should merit emphasis for better understanding of the 
pathogenesis and the long-term prognosis of VSA in the current era. 
 
Conclusions 
The present multicenter study by the Japanese Coronary Spasm Association describes the 
largest observational study of patients with vasospastic angina and cohort who have survived 
cardiac arrest.  Especially, VSA patients who survived OHCA are a high-risk population and 
the importance of continued medications should be emphasized. 
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1,528 patients were assessed for eligibility
1,429 patients were included in the analysis
185 patients were diagnosed based on
spontaneous angina attack
1,122 patients were diagnosed based on
spasm provocation test
122 patients were diagnosed based on
both spontaneous angina attack
and spasm provocation test
99 patients were excluded
because they did not meet
the inclusion criteria
 
Figure 1. Patient flow diagram
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Figure 2. Kaplan-Meier curve for survival (red-line) and major adverse cardiac events 
(MACE) (blue-line) in VSA patients 
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Figure 3. Kaplan-Meier curve for all cause of death and major adverse cardiac events 
(A) The survival rate was comparable between the VSA patients who survived OHCA (red 
line, n=35) and those without OHCA (blue line, n=1,394) (P=0.30). 
(B) Major cardiac events (MACE)-free survival was significantly worse in the VSA patients 
who survived OHCA (red line, n=35) compared with those without OHCA (blue line, 
n=1,394) (P<0.001). 
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Figure 4. The incidence of MACE in patients in whom medications were reduced or 
discontinued (red bar) and that in patients with continued medications (green bar)
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Table 1. Demographic Characteristics of VSA Patients 
 
 Overall Men Women P value 
No. of patients, n (%) 1,429 (100) 1,090 (76) 339 (24) < 0.001 
Age, median (IQR), y 66 (58, 73) 66 (58, 72) 69 (60, 75) < 0.001 
Coronary risk factor, n (%)     
     Hypertension 666 (47) 511 (47) 155 (46) 0.38 
     Dyslipidemia 647 (45) 481 (44) 166 (49) 0.07 
     Diabetes mellitus 233 (16) 186 (17) 47 (14) 0.09 
     Smoking 848 (59) 781 (72) 67 (20) < 0.001 
Family history of IHD, n (%) 168 (12) 118 (11) 50 (15) 0.033 
Previous MI, n (%) 91 (6) 81 (7) 10 (3) 0.003 
Organic stenosis >50%, n (%) 201 (14) 170 (16) 31 (9) 0.001 
ST segment change during spontaneous attack, n (%)     
     ST elevation 272 (19) 234 (21) 38 (11) < 0.001 
     ST depression 121 (8) 83 (8) 38 (11) 0.027 
Arrhythmic event during spontaneous attack, n (%)     
     PVC 14 (1) 12 (1) 2 (1) 0.32 
     VT/VF 17 (1) 14 (2) 3 (1) 0.40 
     AV block 21 (1) 19 (2) 2 (1) 0.09 
     Bradycardia / Sinus pause 28 (2) 20 (2) 8 (2) 0.34 
     Out-of-hospital cardiac arrest † 35 (2) 30 (3) 5 (1) 0.13 
 
† Twenty-six patients (male/female, 23/3 patients) were also complicated by non-fatal VT/VF. 
AV, atrioventricular; IHD, ischemic heart disease; IQR, interquartile range; MI, myocardial infarction; PVC, premature ventricular contraction; 
VF, ventricular fibrillation; VSA, vasospastic angina; VT, ventricular tachycardia.
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Table 2. Arrhythmic Events during Provocation Tests (n=1,244) 
 
 No. of patients, n (%) 
PVC 13 (1.0) 
VT/VF 40 (3.2) 
AV block 8 (0.6) 
Bradycardia/Sinus pause 28 (2.3) 
Total 85 (6.8) 
 
AV, atrioventricular; PVC, premature ventricular contraction; 
VF, ventricular fibrillation; VT, ventricular tachycardia, including both sustained and 
non-sustained VT. 
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Table 3. Correlated factors for Major Adverse Cardiac Events in VSA Patients 
 
 
* Analysis was performed on 8 variables including diabetes mellitus, smoking, previous MI, significant organic stenosis, ST elevation during 
spontaneous attack, history of OHCA, multivessel spasm and administration of β-blockers. 
† Patients complicated by OHCA were not included. 
CI, confidence interval; HR, hazard ratio; IHD, ischemic heart disease; LAD, left anterior descending artery; LCx, left circumflex artery; MI, 
myocardial infarction; OHCA; out-of-hospital cardiac arrest; RCA, right coronary artery; VF, ventricular fibrillation; VT, ventricular tachycardia.
 Univariable analysis  Multivariable analysis * 
 HR 95% CI P value  HR 95% CI P value 
Age 0.99 0.97 - 1.01 0.38     
Men 1.07 0.64 - 1.79 0.79     
Hypertension 0.90 0.58 - 1.38 0.62     
Dyslipidemia 1.17 0.76 - 1.79 0.48     
Diabetes mellitus 1.57 0.94 - 2.61 0.09  1.39 0.82 – 2.34 0.22 
Smoking 1.96 1.21 - 3.19 0.006  1.67 1.02 - 2.73 0.041 
Family history of IHD 1.10 0.58 - 2.06 0.78     
Previous MI 2.19 1.10 - 4.38 0.026  1.39 0.64 - 3.02 0.41 
Significant organic stenosis 2.28 1.39 - 3.73 0.001  2.04 1.21 - 3.44 0.008 
ST elevation during spontaneous attack 1.62 1.01 - 2.60 0.045  1.77 1.09 - 2.87 0.022 
VT/VF during spontaneous attack † 1.00 0.14 - 7.18 1.00     
History of OHCA 3.98 1.73 - 9.13 0.001  3.25 1.39 - 7.61 0.007 
LAD spasm 1.15 0.75 - 1.77 0.51     
LCx spasm 0.92 0.55 – 1.53 0.74     
RCA spasm 1.17 0.76 - 1.78 0.48     
Multivessel spasm 1.45 0.93 - 2.26 0.10  1.62 1.03 - 2.56 0.037 
Administration of β-blockers 2.34 1.08 - 5.06 0.032  1.56 0.64 - 3.79 0.33 
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Table 4. Clinical Characteristics and Angiographic Findings of VSA Patients with and 
those without reduction or discontinuation of medication 
 
 
Reduction/ 
Discontinuation                        
(n=25) 
Continuation                
(n=1,404) P value 
Age, median (IQR), y 65 (58, 72) 66 (58, 73) 0.73 
Men, n (%) 18 (72) 1,072 (76) 0.61 
Coronary risk factor, n (%)    
     Hypertension 12 (48) 654 (47) 0.89 
     Dyslipidemia 10 (40) 637 (45) 0.59 
     Diabetes mellitus 3 (12) 230 (16) 0.40 
     Smoking 18 (72) 830 (59) 0.19 
Previous MI, n (%) 1 (4) 90 (6) 0.52 
ST elevation during spontaneous attack, n (%) 6 (24) 266 (19) 0.34 
Organic stenosis >50%, n (%) 3 (12) 198 (14) 0.52 
Multivessel spasm, n (%) 3 (12) 383 (27) 0.09 
 
IQR, interquartile range; MI, myocardial infarction. 
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Table 5. Demographic Characteristics and Angiographic Findings of VSA Patients with 
and Those without Out-of-Hospital Cardiac Arrest 
 
 
OHCA                        
(n=35) 
Non-OHCA                
(n=1,394) P value 
Age, median (IQR), y 58 (44, 65) 66 (58, 73) < 0.001 
Men, n (%) 30 (86) 1,060 (76) 0.13 
Coronary risk factor, n (%)    
     Hypertension 13 (37) 653 (47) 0.17 
     Dyslipidemia 7 (20) 640 (46) 0.002 
     Diabetes mellitus 4 (11) 229 (16) 0.30 
     Smoking 24 (69) 824 (59) 0.17 
Family history of IHD, n (%) 3 (9) 165 (12) 0.40 
Family history of sudden death, n (%) 0 (0) 19 (1) 0.62 
Previous MI, n (%) 5 (14) 86 (6) 0.07 
Organic stenosis >50%, n (%) 5 (14) 196 (14) 0.56 
     LAD 4 (11) 112 (8) 0.32 
     LCx 1 (3) 62 (4) 0.54 
     RCA 2 (6) 69 (5) 0.53 
ST-segment changes                 
during spontaneous attack, n (%)    
     ST elevation 6 (17) 266 (19) 0.49 
     ST depression 5 (14) 116 (8) 0.17 
Spasm-positive arteries, n (%) †    
     LAD 23 (72) 643 (53) 0.025 
     LCx 11 (34) 306 (25) 0.17 
     RCA 17 (53) 676 (56) 0.45 
     Multivessel 13 (41) 361 (30) 0.13 
 
† Data analyzing 1,244 patients (32 OHCA survivors and 1,212 non-OHCA patients) who 
underwent vasospasm provocation test. 
IQR, interquartile range; LAD, left anterior descending artery; LCx, left circumflex artery; 
OHCA, out-of-hospital cardiac arrest; RCA, right coronary artery. 
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Table 6. Medical Treatments for Patients with and Those without OHCA 
 
 
OHCA                        
(n=35) 
Non-OHCA                
(n=1,394) P value 
Ca channel blockers, n (%) 34 (97) 1,297 (93) 0.29 
Nitrates, n (%) 19 (54) 676 (49) 0.31 
Antiplatelets, n (%) 16 (46) 653 (47) 0.52 
Statins, n (%) 11 (31) 461 (33) 0.50 
ACEI/ARB, n (%) 9 (26) 331 (24) 0.46 
β-blockers 4 (11) 57 (4) 0.06 
 
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; 
Ca, calcium; OHCA, out-of-hospital cardiac arrest. 
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Table 7. Primary and Secondary Endpoints of VSA Patients with and Those without 
Out-of-Hospital Cardiac Arrest 
 
 
OHCA                        
(n=35) 
Non-OHCA                
(n=1,394) P value 
MACE, n (%) 6 (17) 79 (6) 0.015 
     Cardiac death 1 (3) 5 (0.4) 0.14 
     Non-fatal MI 1 (3) 8 (1) 0.20 
     Unstable angina 3 (9) 65 (5) 0.23 
     Heart failure 0 (0) 4 (0.3) 0.91 
     Appropriate ICD shock 2 (5) - - 
All cause death 1 (3) 18 (1) 0.13 
 
ICD, implantable cardioverter defibrillator; MACE, major adverse cardiac event; 
MI, myocardial infarction; OHCA, out-of-hospital cardiac arrest. 
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Table 8. The Clinical Characteristics and Medical Treatments of Patients with and Those 
without ICD implantation 
 
 
With ICD                        
(n=14) 
Without ICD                
(n=21) P value 
Age, median (IQR), y 57 (43, 60) 61 (48, 65) 0.49 
Men, n (%) 12 (86) 18 (86) 0.68 
Previous MI, n (%) 1 (7) 4 (19) 0.32 
Organic stenosis >50%, n (%) 0 (0) 5 (24) 0.06 
ST elevation during spontaneous attack, n (%) 2 (14) 4 (19) 0.54 
Medication, n (%)    
     Ca channel blockers 14 (100) 20 (95) 0.60 
     β-blockers 1 (7) 3 (14) 0.47 
 
Ca, calcium; ICD, implantable cardioverter defibrillator; IQR, interquartile range; 
MI, myocardial infarction. 
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Table 9. Left Ventricular Function and the Prevalence of Organic Coronary Stenosis in 
OHCA Survivors with and without MACE after Discharge 
 
 OHCA survivors (n=35) 
P value 
  (+) MACE (n=5) (-) MACE (n=30) 
LVEF, median (IQR), % 60 (58, 69) 65 (56, 69) 0.83 
     LVEF <50%, n (%) 0 (0) 4 (14) 0.45 
Organic stenosis >50%, n (%) 1 (17) 4 (14) 0.63 
     LAD 0 (0) 4 (14) 0.45 
     LCx 0 (0) 1 (3) 0.83 
     RCA 1 (17) 1 (3) 0.32 
 
IQR, interquartile range; LVEF, left ventricular ejection fraction. 
